-transparent.png){kind=logo}
The origin and development of ischemic heart disease (IHD) is attended with activation of lipid free-radical oxidation facilitating further advancement of the disease and with decrease of the organism's antioxidant protection. The antianginal drugs which are used in IHD treatment differ in their effect on the blood lipid composition and their peroxidation. beta-Adrenoblocking agents may cause proatherogenic disorders of the blood lipid graph, this increases the risk of IHD advancement. Long-acting nitro preparations are lipid-neutral. Calcium antagonists, mainly those of the nifedipin group, suppress LPO superactivity, possess a high antioxidant effect, and, probably, retard the advancement of coronary atherosclerosis and IHD.
V K Serkova, and
V N Zhebel', and
L V Filenko, and
E A Savitskaia
January 2002,
Likars'ka sprava,
V K Serkova, and
V N Zhebel', and
L V Filenko, and
E A Savitskaia
September 1985,
Kardiologiia,
V K Serkova, and
V N Zhebel', and
L V Filenko, and
E A Savitskaia
July 1980,
Kardiologiia,
V K Serkova, and
V N Zhebel', and
L V Filenko, and
E A Savitskaia
January 1997,
Fiziologiia cheloveka,
V K Serkova, and
V N Zhebel', and
L V Filenko, and
E A Savitskaia
January 1976,
Current therapeutic research, clinical and experimental,
V K Serkova, and
V N Zhebel', and
L V Filenko, and
E A Savitskaia
January 1984,
Doklady Akademii nauk SSSR,
V K Serkova, and
V N Zhebel', and
L V Filenko, and
E A Savitskaia
January 1985,
Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury,
V K Serkova, and
V N Zhebel', and
L V Filenko, and
E A Savitskaia
June 1989,
Kardiologiia,
V K Serkova, and
V N Zhebel', and
L V Filenko, and
E A Savitskaia
April 1990,
Kardiologiia,
V K Serkova, and
V N Zhebel', and
L V Filenko, and
E A Savitskaia
January 1988,
Sovetskaia meditsina,
